BCL10

Across TCGA pan-cancer cohorts, BCL10 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCL10 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher BCL10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL10 expression acts as an unfavorable survival marker.

KIRP, SCLC, and UCEC are the cancer types where BCL10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.133	0.605	.014	6	view →
SCLC	DFS	Median	All	0.192	0.793	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCL10–KIRP (DFS)

Open the KIRP breakdown →